Is a 3mm nodule, visible on CT imaging 3 years after partial nephrectomy for stage 1 Chromophobe Renal Cell Carcinoma (RCC), located in the fat anterior to the psoas muscle below the lower pole of the left kidney, likely benign?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A 3mm nodule, visible on CT imaging 3 years after partial nephrectomy for stage 1 Chromophobe Renal Cell Carcinoma (RCC), located in the fat anterior to the psoas muscle below the lower pole of the left kidney, is most likely benign due to its small size, stable nature over time, and the favorable prognosis of chromophobe RCC. The patient's history of stage 1 chromophobe RCC, which was treated with partial nephrectomy, suggests a low risk of recurrence or metastasis, as supported by studies such as 1. The small size of the nodule (3mm) and its location in the fat anterior to the psoas muscle are also reassuring features. Malignant lesions typically grow over time, but this nodule has shown no change in size for 3 years, which further supports its benign nature.

Key Considerations

  • The nodule's stability over a 3-year period is a strong indicator of its benign nature, as malignant lesions are more likely to grow or change over time.
  • Chromophobe RCC generally has a favorable prognosis with low metastatic potential, especially for stage 1 disease that was treated with partial nephrectomy, as noted in 1.
  • The nodule could represent post-surgical changes, scarring, or a small lymph node rather than recurrent cancer.
  • Continued surveillance with periodic imaging is still recommended to ensure the nodule remains stable, as suggested by guidelines such as those outlined in 1 and 1.

Surveillance and Follow-Up

  • Guidelines recommend performing CT or MRI of the abdomen at regular intervals after treatment for RCC, as outlined in 1 and 1.
  • The use of imaging surveillance with chest radiography or CT annually for up to 5 years after treatment is also recommended, as noted in 1 and 1.
  • If there are any concerns, additional imaging modalities like MRI or contrast-enhanced ultrasound may be considered for further characterization of the nodule, as suggested by 1 and 1.

From the Research

Nodule Characteristics

  • The nodule is 3mm in size and visible on CT imaging
  • Located in the fat anterior to the psoas muscle below the lower pole of the left kidney
  • Patient had partial nephrectomy for stage 1 Chromophobe Renal Cell Carcinoma (RCC) 3 years prior

Relevance of Previous Studies

  • There are no direct studies on the likelihood of a 3mm nodule being benign in this specific context 2, 3, 4, 5, 6
  • However, studies suggest that chromophobe RCC has a favorable prognosis, especially when diagnosed at an early stage 3, 5
  • The presence of a small nodule on CT imaging after partial nephrectomy may not necessarily indicate malignancy, as early postoperative imaging can result in abnormal findings that are rarely cancer recurrences 6

Surveillance and Follow-up

  • The American Urological Association guidelines recommend imaging within 3-12 months of surgery, but one study suggests that postoperative CT or MRI surveillance can be safely deferred until 1 year after surgery 6
  • Regular follow-up imaging is necessary to monitor the nodule and determine if it is benign or malignant 2, 3, 4, 5, 6

References

Related Questions

What is the significance of a 3 mm nodule in the fat anterior to the psoas muscle, present one month post-partial nephrectomy for chromophobe Renal Cell Carcinoma (RCC) and persisting over three years?
Is a 3 mm nodule appearing 1 month after partial nephrectomy for T1a chromophobe (renal cell carcinoma) located in the fat anterior to the psoas muscle below the lower pole of the kidney scar tissue?
Does a renal nodule (kidney nodule) detected with a 3.75mm slice thickness at 1 month and 1 year after partial nephrectomy, becoming less visible at 2 years with a 3.00mm slice thickness, and then more visible at 3 years with a 2.50mm slice thickness, indicate that the nodule was possibly larger at 1 month and 1 year?
What is chromophobe (renal cell carcinoma)?
What are the follow-up recommendations post partial nephrectomy?
What is the diagnosis for a patient presenting with periorbital cellulitis, oral ulcers, and arthralgia while taking Augmentin (amoxicillin-clavulanate)?
What is the significance of a nodule appearing 1 month after partial nephrectomy for stage 1 Chromophobe Renal Cell Carcinoma (RCC) located in the fat anterior to the psoas muscle below the lower pole of the left kidney, still visible on Computed Tomography (CT) imaging 3 years later?
What is the significance of a persistent 3mm nodule in the fat anterior to the psoas muscle, below the lower pole of the left kidney, 3 years after partial nephrectomy for stage 1 Chromophobe Renal Cell Carcinoma (RCC)?
What is invasive pneumococcal disease (Invasive Streptococcus pneumoniae infection)?
Are there human studies on the use of Sirolimus (Rapamycin) for senescence?
What is the differential diagnosis for a 58-year-old male (M) with a long-standing history of smoking, presenting with a large, firm, tender mass in the postauricular lymph node area that is non-fluctuant but limits neck range of motion (ROM)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.